96720-15-9

Upstream product

• 96720-13-7 ethyl 5(S),6-epoxy-3(R)-(methoxymethoxy)hexanoate 
• 96720-14-8 (3R,5R)-7-(2,4-Dichloro-phenyl)-5-hydroxy-3-methoxymethoxy-heptanoic acid ethyl ester 
• 96733-91-4 [(2S,4S)-4-(tert-Butyl-diphenyl-silanyloxy)-tetrahydro-furan-2-yl]-acetic acid ethyl ester 
• 96720-10-4 [(2R,4S)-4-(tert-Butyl-diphenyl-silanyloxy)-tetrahydro-furan-2-yl]-acetic acid ethyl ester 
• 96720-08-0 ethyl (S,E)-5,6-dihydroxy-2-hexenoate 
• 96720-12-6 (3R,5S)-6-Bromo-5-(tert-butyl-diphenyl-silanyloxy)-3-methoxymethoxy-hexanoic acid ethyl ester 
• 96720-11-5 (3R,5S)-6-Bromo-5-(tert-butyl-diphenyl-silanyloxy)-3-hydroxy-hexanoic acid ethyl ester 
• 96720-09-1 ethyl 6-<(tert-butyldiphenylsilyl)oxy>-5(S,E)-hydroxy-2-hexenoate 
• 96720-07-9 (E)-ethyl 4-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)but-2-enoate 

Downstream Products

• 90761-31-2 7-(2,4-Dichlorophenyl)-D-erythro-3-hydroxy-5-heptanolide 

Relevant academic research and scientific papers

Process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein

This invention relates to a novel process for the preparation of 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase inhibitors which contain a 4-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one moiety, such as compactin and mevinolin, by utilizing an alkyl

PREPARATION OF ETHYL 5(S),6-EPOXY-3(R)-(METHOXYMETHOXY)HEXANOATE: A KEY CHIRAL INTERMEDIATE FOR MEVINOLIN AND COMPACTIN.

The synthesis of Ethyl 5(S),6-Epoxy-3(R)-(methoxymethoxy)hexanoate, a key chiral synthon for the β-hydroxy-δ-lactone portion of Mevinolin and Compactin, via a regiospecific ring opening of a tetrahydrofuran derivative by dimethyboron bromide, is described.